SCAI 2024 Scientific Sessions, the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI), runs May 2-4 in Long Beach, California.
Interventional cardiologists and endovascular specialists from all over the world are expected to attend the three-day event. The meeting will feature dozens of educational session and hundreds of abstracts focused on improving care for patients presenting with heart disease and other cardiovascular concerns.
“At this year’s SCAI Scientific Sessions, we are seeing a broad range of clinical trials and emerging science all with the same aim—improving patient outcomes and experience,” SCAI Interventional Cardiology Program Chair J. Dawn Abbott, MD, director of the interventional cardiology and cardiac catheterization laboratories at the Lifespan Cardiovascular Institute, said in a statement. “Featuring numerous abstracts with fresh insights into health disparities, efficacy data for TAVR, and innovative strategies for PAD, we eagerly anticipate the convergence of professionals from diverse specialties. Their teamwork and collaboration allows us to advance collective efforts within this sector, driving forward innovation and enhancing patient care.”
“We are proud to offer over 80 sessions in a variety of interactive educational formats at this year’s meeting,” added SCAI President George D. Dangas, MD, PhD, a professor at the Mount Sinai School of Medicine and director of cardiovascular innovation at the Zena and Michael A. Weiner Cardiovascular Institute of the Mount Sinai Medical Center. “We believe the tools, resources and information shared at the meeting will provide the healthcare community with greater expertise to improve patient outcomes and also connect with their interventional cardiology colleagues.”
Key sessions at SCAI 2024 Scientific Sessions
Transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD) and percutaneous coronary intervention (PCI) are just some of the topics that will be featured at SCAI 2024 Scientific Sessions. Some of the most notable announced for the meeting include these late-breaking presentations:
- Temporal trends and clinical outcomes with radial versus femoral arterial access for PCI in the United States | Thursday, May 2 | 9:17-9:24 a.m.
- Self-expanding versus balloon-expandable TAVR in patients with small aortic annuli: Additional outcomes from the SMART trial | Friday, May 3 | 2:44-2:51 p.m.
- Update from the first-in-human study with the novel DurAVR biomimetic transcatheter heart valve | Friday, May 3 | 10:55-11:00 a.m.
- Revascularization strategies in patients with peripheral arterial disease involving the femoropopliteal arteries: A pooled analysis of individual patient data | Friday, May 3 | 3:12-3:19 p.m.
Click here for additional details.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.